- 바이오사이토젠, HKEX 메인보드 상장… 주류 신약 기업 목표
- 2022년 9월 2일 15:30
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- BioMice Business Summary (Graphic: Business Wire)
- 2023년 9월 1일 11:00
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
- 2023년 9월 17일 15:40
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
- 2025년 7월 11일 10:20
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
- 2025년 9월 5일 17:15
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
- 2025년 9월 17일 10:05
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
- 2025년 12월 5일 17:15
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Successfully Lists on the STAR Market
- 2025년 12월 12일 10:00
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
- 1월 13일 14:00
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.